Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Amneal Pharmaceuticals has acquired Kashiv BioSciences, a pharmacy business in New Jersey, for an undisclosed amount. Kashiv BioSciences develops and commercializes biosimilars, supporting Amneal Pharmaceuticals’ plan to expand a fully integrated global biosimilars platform. Amneal Pharmaceuticals acquisitions in healthcare M&A focus on strengthening manufacturing, regulatory, and market access capabilities tied to biosimilar products. The merger acquisition is a strategic acquisition by a strategic buyer, positioning Amneal Pharmaceuticals for broader global scale in biosimilars. Deal status is announced, with terms and closing timing not disclosed.
Source
Read full article on businesswire.comvia GN - entered into definitive agreement · April 27, 2026
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026